Key result
Blood lipid determinations at 1 year of age are highly superior to those at birth for diagnosing familial hypercholesterolemia, with mean total cholesterol of affected vs nonaffected infants.
Why the study?
Does lipid determination at 1 year of age improve the diagnostic accuracy of familial hypercholesterolemia compared to cord blood testing at birth in newborns with a family history?
Cohort (n=72)
Does lipid determination at 1 year of age improve the diagnostic accuracy of familial hypercholesterolemia compared to cord blood testing at birth in newborns with a family history?
Lipid determinations at 1 year of age are highly superior to cord blood testing at birth for the diagnosis of familial hypercholesterolemia, as lipid levels show non-overlapping ranges between affected and non-affected infants at 1 year.
Answers are grounded in this paper and cite their sources.
May support 1-year over birth lipid testing for FH diagnosis in at-risk infants; leaves open prospective validation before practice change.
This study was designed to compare blood lipid levels in newborn individuals with molecularly defined heterozygous familial hypercholesterolemia [FH] to those in non-affected babies and to clarify the value of lipid determinations in assessment of diagnosis of FH at birth and 1 year of age. Twenty-five babies were born to 21 parents with DNA-documented heterozygous FH. Analysis of their cord blood samples revealed 11 newborns with the FH-North Karelia [FH-NK] mutation, 3 newborns with the FH-Helsinki [FH-HKI] mutation, and 11 nonaffected newborns. Cord serum total [TC] and LDL cholesterol [LDL-C] levels (mean +/- SD) in affected newborns (2.60 +/- 0.70 and 1.77 +/- 0.56, respectively) were significantly (P < .001) higher than those in nonaffected ones (1.54 +/- 0.23 and 0.78 +/- 0.15, respectively) and another cohort of 30 randomly selected control samples from apparently healthy newborns (1.84 +/- 0.46 and 1.03 +/- 0.30, respectively). However, there was overlapping of individual lipid levels in these three groups precluding the use of TC or LDL-C determinations in neonatal diagnosis of FH. In contrast, 1 year follow-up samples from 10 affected and 7 nonaffected individuals, as well as additional samples collected from another group of 8 affected and 9 nonaffected individuals, indicated that serum cholesterol levels showed much greater increment in children with FH. Thus, at the age of 1 year the mean serum TC and LDL-C levels in the affected infants (8.38 +/- 1.18 and 7.02 +/- 1.07, respectively) were much higher (P < .001) than the corresponding levels (4.40 +/- 0.66 and 2.89 +/- 0.68, respectively) in the nonaffected infants, and the individual ranges of TC and LDL-C levels were nonoverlapping in these two groups. Serum HDL cholesterol [HDL-C] levels in 1-year-old children with FH (0.95 +/- 0.14) were approximately 20% lower than those of their similar at birth. In conclusion, phenotypic expression of heterozygous FH, as defined by molecular analysis of genomic DNA, is evident in serum LDL-C (but not HDL-C) levels already at birth, but for diagnostic purposes blood lipid determinations carried out at the age of 1 year are highly superior to those performed at birth.
No takes yet. Share an insight, caveat, or question.
Vuorio et al. (1997) conducted a cohort in Heterozygous familial hypercholesterolemia (n=72). Blood lipid determination at 1 year of age vs. Blood lipid determination at birth was evaluated on Mean serum total cholesterol at 1 year of age (p=<.001). Blood lipid determinations at 1 year of age are highly superior to those at birth for diagnosing familial hypercholesterolemia, with mean total cholesterol of affected vs nonaffected infants.
Synapse has enriched 10 related papers. Consider them for comparative context: